A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer.
Phase of Trial: Phase II
Latest Information Update: 09 May 2018
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms KeyLargo
- 09 Feb 2018 Status changed from not yet recruiting to recruiting.
- 21 Nov 2017 New trial record